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ORIGINAL ARTICLE
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus
inﬂuenzae in an in vitro kinetic model: a comparison of different dosage
regimens including a pharmacokinetically enhanced formulation
E. Lo¨wdin, O. Cars and I. Odenholt
Antibiotic Research Unit, Department of Infectious Diseases and Clinical Microbiology, University
Hospital, Uppsala, Sweden
Objective To study the pharmacodynamics of amoxicillin/clavulanic acid against dif-
ferent strains of Haemophilus inﬂuenzae in an in vitro kinetic model. The concentrations
used corresponded to human serum levels obtained after 875mg amoxicillin/clavulanic
acid given b.i.d, 500/125mg amoxicillin/clavulanic acid given t.i.d. and those obtained
with a pharmacokinetically enhanced formulation containing 1125/125mg amoxicillin/
clavulanic acid (immediate release) and 875mg amoxicillin (sustained release) given
b.i.d.
Methods Bacteria at an initial inoculum of 106 colony-forming units (CFU)/mL were
exposed to amoxicillin/clavulanic acid with an initial concentration of approximately
15/3mg/L, 8/3mg/L simulating the peak levels in humans achieved after a dose of 875/
125mg and 500/125mg with a half-life of 1 h. In addition, experiments with a 2000/
125mg pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid given
b.i.d were performed. A repeated dose was given at 12 h after the initial dose of 875/
125mg and the pharmacokinetically enhanced formulation or at 8 and 16 h after the dose
of 500/125mg. The experiments were performed in an in vitro kinetic model, which
consists of a spinner ﬂask with a ﬁlter membrane ﬁtted in between the upper part and the
bottom part in order to prevent bacterial dilution. The medium is removed from the
culture ﬂask, through the ﬁlter, at a constant rate with a pump. Repeated samples were
taken at intervals of 1–2 h up to 24 h during the experiments for viable counting. One of
the strains ofH. inﬂuenzaewas also exposed to a constant concentration corresponding to
the peak serum levels obtained after a dose of 500/125mg.
Results The concentrations of amoxicillin in the in vitro kinetic model were as expected.
At the end of the experiment (24 h), there was a tendency for a greater bactericidal effect
with 500/125mg t.i.d, as compared to 875/125 b.i.d., with differences in CFUs between
the two dosing regimens of 2.6 log10 CFU for H. inﬂuenzae LH 2803 and 1.8 log10 CFU for
the other clinical strains. However, these differences did not reach statistical signiﬁcance
(P¼ 0.075 and 0.10, respectively). A statistically signiﬁcant higher bactericidal effect was
seen in the experiments with the pharmacokinetically enhanced formulation in compar-
ison with the b.i.d. regimen both at 8, 16 and 24 h and at 8 and 16 h with the t.i.d. regimen.
With the new formulation, no regrowth was seen at 24 h, similar to the results obtained
with a constant concentration.
Conclusions Neither of the standard dosing regimens of amoxicillin (875/125mg b.i.d.
or 500/125mg) used in our study, in which the time that the free (non-protein-bound)
concentration theMIC (T>MIC) exceeding was less than 50%, was sufﬁcient to achieve a
complete bactericidal effect during the ﬁrst 24 h of treatment. However, a statistically
signiﬁcant difference in bactericidal activity was seen at 8, 16 and 24 h vs. the b.i.d.
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regimen and at 8 and 16 h vs. the t.i.d. regimen with the pharmacokinetically enhanced
formulation. This formulation gave a longer T>MIC (73–79%) of amoxicillin even
though the concentration of clavulanic acid was only detectable for 45% of the dosing
interval, and complete killing of all strains was obtained after 24 h.
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INTRODUCTION
In the early era of antimicrobials, it was suggested
that the concentration of penicillin should bemain-
tained above the minimum inhibitory concentra-
tion (MIC) throughout the dosage interval [1].
However, during the clinical development of
new b-lactam antibiotics, intermittent dosing with
relatively long dosing intervals was shown to be
effective despite the rapid elimination of most of
these compounds. The optimal dosing regimen for
antimicrobial agents is, however, still not fully
explored. In general, b-lactam antibiotics are
known to exhibit a non-concentration-dependent
killing, their efﬁcacy is mainly dependent on the
time that the free (non-protein-bound) concentra-
tion stays above the MIC (T>MIC) [2–4]. The
exact fraction of the dosage interval during which
this concentration should be exceeded for optimal
clinical efﬁcacy is, however, not known and may
vary according to the type of b-lactam antibiotics
and the site of infection.
Different dosing regimens for amoxicillin and
clavulanic acid are currently used in clinical prac-
tice [5]. A new formulation of amoxicillin with
clavulanic acid is presently under clinical evalua-
tion [6]. The rationale behind this development
is to increase the T>MIC and thus optimize
the efﬁcacy against respiratory pathogens, e.g.
Haemophilus inﬂuenzae and Streptococcus pneumo-
niae [6].
The aim of the present investigation was to
compare the bactericidal activity of a pharmaco-
kinetically enhanced formulation of amoxicillin/
clavulanic acid with the currently available for-
mulations given, either 875/125mg b.i.d or 500/
125mg t.i.d., against different strains of b-lacta-




Amoxicillin and clavulanic acid were provided
by Astra/Zeneca, So¨derta¨lje, Sweden and Smith-
Kline Beecham Pharmaceuticals, Worthing, West
Sussex, UK. The antibiotic and clavulanic acid
were obtained as reference powders with known
potency. Fresh solutions were made prior to each
experiment.
Bacterial strains and medium
The strains used in the study included one strain of
TEM-1 b-lactamase-producing H. inﬂuenzae LH
2803 obtained from SmithKline Beecham Pharma-
ceuticals and clinical isolates of b-lactamase-pro-
ducing H. inﬂuenzae (3029, 2012, 1041, 2045)
obtained from the ClinicalMicrobiological Labora-
tory, Uppsala University Hospital, Sweden. The
strains were grown for 6 h at 37 8C in Mueller–
Hinton broth (Difco Laboratories, Detroit, MI,
USA), supplemented with 30mg/L of haemin and
1% of IsoVitaleX yielding an inoculum of approxi-
mately 109 colony-forming units (CFU)/mL.
Minimum inhibitory concentrations (MICs)
The MICs of all strains were performed with E test
(amoxicillin/clavulanic acid 2 : 1; Biodisk, Solna,
Sweden).
Concentrations of amoxicillin and clavulanic
acid
The concentrations of amoxicillin were deter-
mined by microbiological agar diffusion methods,
using Bacillus stearothermophilus ATCC 3032 as the
test organism [7]. A standardized inoculum of
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spore suspension was mixed with tryptone–glu-
cose agar, adjusted to pH7.4 and plates were
poured. After drying the plates, 0.01mL volumes
of all samples and standards diluted in Mueller–
Hinton broth, supplemented with 30mg/L of hae-
min and 1% of IsoVitaleX were placed in agar
wells and three parallel determinations were
made. The concentrations of clavulanic acid were
determined with microbiological agar diffusion
method using Klebsiella pneumoniae ATCC 29665
as the test organism. In order to determine the
zones of clavulanic acid in these latter determina-
tions, the agar plates also contained benzylpeni-
cillin at a concentration of 6mg/L. After drying
the plates, 0.03mL volumes of all samples and
standards were placed in agar wells and three
parallel determinations were made. The limit of
detection was 0.031mg/L for amoxicillin and
0.1mg/L for clavulanic acid. The correlation coef-
ﬁcient for the standard curves was always >0.99
and the coefﬁcient of variation on samples ana-
lysed on different days was 9%.
In vitro kinetic model
A previously described in vitro kinetic model was
used in these experiments [8,9]. It consists of a
spinner ﬂask with a 0.45-mmﬁlter membrane and a
preﬁlter ﬁtted in between the upper and the bot-
tom part. Amagnetic stirrer ensures homogeneous
mixing of the culture and preventsmembrane pore
blockage. In one of the side-arms of the culture
vessel, a silicon membrane is inserted to enable
repeated sampling. A thin plastic tubing to a vessel
containing fresh medium is connected with the
other arm. The medium is removed from the
culture ﬂask, through the ﬁlter, at a constant rate
with a pump. Fresh sterile medium is taken into
the ﬂask at the same rate by the negative pressure
built up inside the culture vessel. In the experi-
ments simulating the twice (b.i.d.) and thrice
(t.i.d.) daily regimens, the antibiotic was added
to the vessel and eliminated at a constant rate
according to the ﬁrst order kinetics C¼C0 ekt
where C0 is the initial antibiotic level, C is the
antibiotic level at the time t, k is the rate of elim-
ination, and t is the time elapsing since the addi-
tion of antibiotic. In the experiments simulating
the concentrations of the pharmacokinetically
enhanced formulation compound, an absorption
phase of amoxicillin/clavulanic acid was also
included. To mimic the concentration of this for-
mulation, amoxicillin was diluted at the rate cor-
responding to the half-life of clavulanic acid and
the incoming medium was supplemented with
amoxicillin at a rate corresponding to its longer
half-life. In order to obtain this, two vessels con-
taining amoxicillin at adequate concentrations
were connected in series to the culture vessel.
The apparatus was placed in a thermostatic room
at 37 8C during the experiments.
Bacterial killing following exposure to
simulated human pharmacokinetics
875/125mg b.i.d. and 500/125mg t.i.d. of
amoxicillin/clavulanic acid
Bacteria, at an initial inoculum of approximately
106 CFU/mL, were exposed to amoxicillin/clavu-
lanic acid with an initial concentration of approxi-
mately 15/3mg/L or 8/3mg/L, simulating the
peak levels in humans achieved after doses of
875/125mg and 500/125mg, respectively. The
simulated half-life was 1 h. A repeat dose was
given at 12 h after the initial dose of 875/125mg
or at 8 and 16 h after the dose of 500/125mg.
Repeat samples were taken at 0, 2, 4, 5, 6, 7, 8, 9,
12, 14, 16 and 24 h during the b.i.d. experiments
and at 0, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20 and
24 h during the t.i.d. experiments for viable count-
ing. The samples were, if necessary, diluted in
phosphate-buffered saline and three dilutions of
each sample were spread on blood agar plates
(Colombia agar base with 5% horse blood) incu-
bated at 37 8C in 5% CO2 in air and counted after
24 h. The reference strain of H. inﬂuenzae was
investigated four times on different occasions with
both dosage regimens. The clinical strains were
studied once at each dosing regimen. Control
cultures were grown in glass tubes.
2000/125mg pharmacokinetically enhanced
amoxicillin/clavulanic acid b.i.d.
The bacterial strains with an initial inoculum of
approximately 106CFU/mL were exposed to
amoxicillin/clavulanic acid, simulating human
pharmacokinetics of the pharmacokinetically
enhanced formulation (see Figure 1). This for-
mulation contains 1125/125mg amoxicillin/cla-
vulanic acid (immediate release) and 875mg
amoxicillin (sustained release) given b.i.d [6].
A repeat dose was given at 12 h. Repeat samples
were taken at 0, 1, 2.5, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5,
12, 13, 14.5, 17.5 and at 24 h for viable counting. The
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samples were cultured as previously described.H.
inﬂuenzae LH 2803 was investigated in triplicate.
The clinical strains were studied once. Control
cultures were grown in glass tubes.
Static concentrations of amoxicillin/clavulanic acid
in the in vitro kinetic model
The rate and extent of killing of amoxicillin/cla-
vulanic acid againstH. inﬂuenzae LH 2803 was also
investigated with a constant antibiotic concentra-
tion, corresponding to the peak serum levels
obtained after a dose of 500/125mg of amoxicil-
lin/clavulanic acid (8/3mg/L) This was achieved
by adding amoxicillin/clavulanic acid to the fresh
medium during the experiments. Samples were
withdrawn at 0, 2, 4, 6, 8, 10 and 24 h and seeded
and counted as described before. Four experi-
ments were performed on different occasions.
Statistics
The student’s t-test for unpaired sampleswas used
to compare the bactericidal activities after 24 h of
825/125mg b.i.d with 500/125mg t.i.d of amox-
icillin/clavulanic acid and to compare the phar-
macokinetically enhanced formulation with the
b.i.d. and t.i.d. regimens at 8, 16 and 24 h.
RESULTS
Minimum inhibitory concentrations
TheMIC value for amoxicillin/clavulanic acidwas
0.5mg/L for H. inﬂuenzae LH 2803. The remaining
four strains had a MIC of 0.75mg/L
Simulated pharmacokinetics of amoxicillin and
clavulanic acid
The concentrations of amoxicillin 875mg, 500mg
and the concentrations achieved with the pharma-
cokinetically enhanced formulation are shown in
Figure 1. The concentrations of clavulanic acid
were as expected and covered 45% of the 24 h
with the b.i.d regimen and 69% of the t.i.d.
regimen. Table 1 shows the pharmacokinetic/
Figure 1 The concentration of amox-
icillin in the in vitro kinetic model
corresponding to a dose of 875mg
b.i.d. (^), 500mg t.i.d. (&) and of
the pharmacokinetically enhanced
formulation 2000mg b.i.d. (~).
Table 1 Pharmacodynamic parameters of the different dosages of amoxicillin
825mg b.i.d. 500mg t.i.d 2000mg b.i.d.
Strain Cmax/MIC T>MIC24 Cmax/MIC T>MIC24 Cmax/MIC T>MIC24





22.4 38% 11.7 44% 20.3 73%
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pharmacodynamic indices for the different dosing
regimens.
Bacterial killing following exposure to
simulated human pharmacokinetics
875/125mg b.i.d and 500/125mg t.i.d of
amoxicillin/clavulanic acid
After exposure to concentrations simulating those
obtainedwith an oral dose of 875/125mg and 500/
125mg amoxicillin/clavulanic acid, a bactericidal
effect of 3–4 log10 CFU/mL was seen initially. This
was noted for all the investigated strains. Repeated
doses after 8 and 16 h (t.i.d. regimen) exerted a
further bactericidal effect. At the end of the experi-
ment (24 h), there was a tendency towards a lower
bacterial count with the t.i.d regimen in compar-
ison with the b.i.d. regimen with differences in
CFUs of 2.6 log10 CFU and 1.8 log10 CFU for H.
inﬂuenzae LH 2803 (Figure 2) and the other clinical
strains, respectively (Figure 3a,b). However, these
differences did not reach statistical signiﬁcance
(P¼ 0.075 and 0.10, respectively).
2000/125mg pharmacokinetically enhanced
amoxicillin/clavulanic acid b.i.d.
In the experiments simulating the pharmacokine-
tically enhanced formulation, a bactericidal effect
of 4–5 log10 CFU/mL was obtained initially in
all experiments. There was a statistically greater
bactericidal effect of the pharmacokinetically
enhanced formulation in comparison with the
standard b.i.d regimen at 8, 16 and 24 h (P<
0.01) and at 8 and 16 h (P< 0.01) in comparison
with the t.i.d. regimen. In the experiments with the
pharmacokinetically enhanced formulation, no
regrowth was seen except for one of the clinical
strains (Figure 4). This strain started to grow
between 8 and 9h but after the second dose at
12 h, a bactericidal effect was obtained and no
further regrowth was noted. This was conﬁrmed
in two additional experiments.
Static concentrations of amoxicillin/clavulanic acid in
the in vitro kinetic model
No regrowth of H. inﬂuenzae LH 2803 was noted
when the bacteria were exposed to amoxicillin/
clavulanic acid at a constant concentration of 8/
3mg/L. At 24 h there was a 5 log10 decrease in
viable counts.
DISCUSSION
The goal of antimicrobial therapy is to maximize
the bactericidal activity against the infecting
pathogen. Results from in vitro studies and studies
in animals have shown that different classes of
antibiotics behave differently with respect to phar-
macodynamic properties. For optimal therapy it is
important to take into consideration both pharma-
cokinetic and pharmacodynamic parameters [2–4].
b-Lactam antibiotics exhibit a minimal concentra-
tion-dependent killing, have a short or no post-
antibiotic effect or none and it has been shown that
the duration of the time that serum concentrations
exceeds the MIC (T>MIC) is the important para-
meter for efﬁcacy [2,10,11]. However, studies in
animal models have demonstrated that the anti-
biotic concentrations do not need to exceed the
MIC for thewhole dosing interval. Craig et al. have
Figure 2 The rate and extent of kill-
ing of amoxicillin/clavulanic acid at
a concentration corresponding to a
dose of 875/125mg b.i.d. (&) and
500/125mg t.i.d. (^) against H.
influenzae LH 2803 in the in vitro
kinetic model (mean SD).
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Figure 3 (a) The rate and extent of
killing of amoxicillin/clavulanic
acid at a concentration correspond-
ing to a dose of 875/125mg b.i.d.
against the clinical strains of H.
influenzae in the in vitro kinetic
model (mean SD). (b) The rate
and extent of killing of amoxicillin/
clavulanic acid at a concentration
corresponding to a dose of 500/
125mg t.i.d. against the clinical
strains of H. influenzae in the in vitro
kinetic model.
Figure 4 The rate and extent of kill-
ing of amoxicillin/clavulanic acid
simulating the slow-release com-
pound against H. influenzae LH
2803 and the clinical strains of H.
influenzae in the in vitro kinetic
model (mean SD).
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shown, in thigh and lung infection models in
neutropenic mice, that the T>MIC for b-lactam
antibiotics against Streptococcus pneumoniae need-
ed to be approximately 40–50% of the dosage
interval in order to achieve a 90–100% survival
of the mice after 4 days of treatment. When the
T>MIC was 20%, the mortality was almost
100% [3]. In another study in neutropenic mice,
byAndes andCraig, the breakpoints of amoxicillin
against S. pneumoniae were investigated [12]. They
also showed that for the mice to survive after
4 days of treatment, a T>MIC of 40% of the 8-h
dosing interval was required [12].
Concerning clinical trials, Craig and Andes
compiled data retrospectively that included
patients with otitis media caused by S. pneumoniae
and H. inﬂuenzae, where the microbiological efﬁ-
cacy was followed by repeated tympanocenteses.
They found that an increased time during which
free serum levels were above the MIC (calculated
from published serum pharmacokinetic data in
pediatric populations) correlated with an in-
creased bacteriological eradication of the infecting
pathogens. To achieve an 80–85% bacteriological
cure rate of both cephalosporins and penicillins
against the two pathogens, T>MIC of 50% and
40%, respectively, was required [3]. Recently,
Dagan et al. have published data on bacterial er-
adication in the treatment of sinusitis, and found
the sameﬁgures forT>MICaswithotitismedia [4].
In the present study, when simulating the phar-
macokinetics following a dose of 875/125mg of
amoxicillin/clavulanic acid b.i.d or 500/125mg
t.i.d, we consistently found regrowth shortly after
the concentrations had declined under the MIC
and neither dosage regimen was completely bac-
tericidal during this short-term experiment. The
mean times for which amoxicillin concentrations
exceededMIC during the 24 h experimental period
after a simulated dose of 875/125mg b.i.d. were
42% and 38% for H. inﬂuenzae LH 2803 and the
clinical isolates, respectively. For the 500/125mg
t.i.d. regimen, the corresponding ﬁgures were 50%
and 44%. The longer T>MIC in the latter experi-
ments is in accordance with the tendency in our
experiments towards a better efﬁcacy with the
t.i.d. regimen, although this difference was not
statistically signiﬁcant. It should be noted, how-
ever, that an absorption phase, which would have
extended the T>MIC somewhat, was not in-
cluded in these experiments. In the experiments
with the pharmacokinetically enhanced formula-
tion, regrowth was only noted for one clinical
strain (1041), which started to grow at MIC, but
was eradicated after the second dose. The T>MIC
in these experiments was 79% for H. inﬂuenzae LH
2803 and 73% for the other strains with a MIC of
0.75mg/L. It is notable that the detectable concen-
tration of clavulanic acid in these experiments was
only present for 45% of the 24 h. The lack of
regrowth despite a non-detectable clavulanic acid
concentration may be explained by the post-b-
lactamase inhibitor effect [13]. In the experiments
with static concentrations, where the T>MIC was
100% during the study period, no regrowth was
observed.
Our in vitro model, like others, does not include
the potential synergistic effects between the anti-
biotic and immune defence factors and may thus
reﬂect the situation in an immunocompromised
host rather than in a normal patient. Neither of the
dosing regimens used in our study, in which
T>MIC of amoxicillin was less than 50%, was
sufﬁcient to achieve a complete bactericidal effect
during the ﬁrst 24 h of treatment. However, when
the concentrations of the pharmacokinetically
enhanced formulation were simulated, giving a
longer T>MIC of amoxicillin even though the
concentration of clavulanic acid was similar to
those in the ﬁrst experiments, complete killing
of all strains was obtained after 24 h. Our results
are in agreement with others [2–4] in that a better
antibacterial efﬁcacy was achieved with the regi-
men with longer T>MIC. This was further con-
ﬁrmed in the experiments where the reference
strain was exposed to amoxicillin/clavulanic acid
for 100% of the experimental time, which gave a
complete kill of the bacteria.
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